The Comprehensive Pathophysiological Changes in a Novel Rat Model of Postinflammatory Visceral Hypersensitivity
Overview
Affiliations
So far, a comprehensive animal model that can mimic both the central and peripheral pathophysiological changes of irritable bowel syndrome (IBS) is lacking. Here, we developed a novel IBS rat model combining trinitro-benzene-sulfonic acid (TNBS) and chronic unpredictable mild stress (CUMS) (designated as TC-IBS) and compared it with the TNBS-induced and CUMS-induced models. TC-IBS showed a pronounced depression phenotype with increased corticotropin-releasing hormone receptor (CRHR)1 and CRHR2 expression at the frontal cortex and increased serum ACTH concentration. Visceral hypersensitivity (VH), as evidenced by colorectal distention (CRD) test, was highest in TC-IBS, accompanied by increased serum 5-hydroxytryptamine (5-HT) level and colonic 5-HT receptor 3A (5-HTR)/5-HT receptor 2B expression, impaired tight junction protein expression including occludin, zonula occludens-1, and phosphorylated myosin light chain. Palonosetron, a second generation of 5-HTR antagonist, alleviated VH significantly in TC-IBS. 16S rRNA sequencing showed that TNBS plus CUMS induced a significant disturbance of the gut microbiota. Cytokine profile analysis of TC-IBS model indicated an innate immune activation both in serum and colonic mucosa. Further, fecal microbiota transplantation improved VH and some pathophysiological changes in TC-IBS. In summary, we established a postinflammatory IBS model covering multifactorial pathophysiological changes, which may help to develop therapies that target specific IBS subtype.-Ma, J., Li, J., Qian, M., He, N., Cao, Y., Liu, Y., Wu, K., He, S. The comprehensive pathophysiological changes in a novel rat model of postinflammatory visceral hypersensitivity.
Microbiome contributions to pain: a review of the preclinical literature.
Pratt M, Plumb A, Manjrekar A, Cardona L, Chan C, John J Pain. 2024; 166(2):262-281.
PMID: 39258679 PMC: 11723818. DOI: 10.1097/j.pain.0000000000003376.
Pathology of pain and its implications for therapeutic interventions.
Cao B, Xu Q, Shi Y, Zhao R, Li H, Zheng J Signal Transduct Target Ther. 2024; 9(1):155.
PMID: 38851750 PMC: 11162504. DOI: 10.1038/s41392-024-01845-w.
Jiang H, Li R, Zhang F, Zhou F, Lin J, Kong N Oxid Med Cell Longev. 2023; 2023:4463063.
PMID: 36713031 PMC: 9879690. DOI: 10.1155/2023/4463063.
Staal R, Gandhi A, Zhou H, Cajina M, Jacobsen A, Hestehave S Purinergic Signal. 2022; 18(4):499-514.
PMID: 36001278 PMC: 9832206. DOI: 10.1007/s11302-022-09892-0.
Zhao Y, Jiang H, Shi Y, Zhang W, Zhang L, Hou Y Evid Based Complement Alternat Med. 2022; 2022:2497430.
PMID: 35198032 PMC: 8860523. DOI: 10.1155/2022/2497430.